Table 3. Phenotypic classification of defects obtained following suppression of expression under RNAi.

Accession (geneDB)	Annotation	Proliferation1	Morphology2	Vesiculated ER	Swollen ER	Multinucleated	Increase in level of
							VSG	ISG65	ISG75
11.02.5450/5500	BiP	+	+		++	++	−
09.160.3090	Hsp70 (Imported to ER)	+	+	+	−	++	+	+	−
09.211.1390	Hsp70 (Imported to ER)	+	+	−	−	−	−	−	−
11.01.3110	Hsp70 (cytosolic)	+	+	++	++	−	−	−	−
927.3.3580	GRP94/LPG3	−
927.3.1430	DNAj	−
11.01.8480	DNAj	−
09.211.3680	DNAj	+	+	−	+	+	++	++	+/−
10.70.5440	DNAj	+	+	−	+	−	++	+/−	+/−
927.4.5010/927.8.7410	Calreticulin	+	+	+/−	++	++	+	+/−	+/−
10.05.0080	ER glucosidase II	+	+	−	+/−	++	++	−	−
927.8.2910/2920/2930/2940	EDEM A	+	+	−	+	++	+
	EDEM B	+	+	−	+/−	++	+
927.3.4630	Glycoprotein glucosyltransferase	+	+	−	+/−	+/−	++	−	−
11.01.2470	Yos9	−
11.02.1680	ERGIC53	−
10.20.0130	Vip36	+	+	−	+	+	++
927.7.13003	ERp72	+	−	−	−	−
10.6k15.2290	ERp57	+	+	−	+	++	++	+/−	+/−
927.8.4890	Ero1	+	+	−	+/−	+	−
927.7.5790	ERp44	+	+	−	+	++	+
927.4.4740	Lag1/Dgt1	−
11.02.4100	Sec61	+	+	−	++	++	+	+	+

All experiments were conducted in bloodstream stages and analysis of cells performed after one and two days induction.

¹Proliferation score: +; greater than 20% proliferation defect observed on at least two consecutive days.

²Morphological and protein expression changes are scored as follows: ++; strong (expression level at least twice control, abnormal morphology in more than 50% of cells and severe), +; moderate (expression level up to twice control, morphology in up to 50% of cells and obvious), +/−; mild (expression level changes less than twice control, morphology in fewer than 50% of cells and not pronounced), and −; no detectable change. Blank; no data.

³Tb927.7.1300 (ERp72) – this cell line has not been analysed by IFA or Western as positive clones could not be expanded.